Frontiers in Cardiovascular Medicine (Jul 2023)
Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy
- Zehao Zhao,
- Zehao Zhao,
- Zehao Zhao,
- Shutong Dong,
- Shutong Dong,
- Shutong Dong,
- Tienan Sun,
- Tienan Sun,
- Tienan Sun,
- Kangning Han,
- Kangning Han,
- Kangning Han,
- Xin Huang,
- Xin Huang,
- Xin Huang,
- Meishi Ma,
- Meishi Ma,
- Meishi Ma,
- Shiwei Yang,
- Shiwei Yang,
- Shiwei Yang,
- Yujie Zhou,
- Yujie Zhou,
- Yujie Zhou
Affiliations
- Zehao Zhao
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Zehao Zhao
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Zehao Zhao
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Shutong Dong
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Shutong Dong
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Shutong Dong
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Tienan Sun
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Tienan Sun
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Tienan Sun
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Kangning Han
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Kangning Han
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Kangning Han
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Xin Huang
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Xin Huang
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Xin Huang
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Meishi Ma
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Meishi Ma
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Meishi Ma
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Shiwei Yang
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Shiwei Yang
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Shiwei Yang
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- Yujie Zhou
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- Yujie Zhou
- Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China
- Yujie Zhou
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China
- DOI
- https://doi.org/10.3389/fcvm.2023.1250733
- Journal volume & issue
-
Vol. 10
Abstract
No abstracts available.Keywords
- free fatty acids (FFA)
- coronary artery disease
- clopidogrel
- platelet reactivity
- thromboelastogram
- percutaneous coronary intervention
